Yes, so long as the patient was able to tolerate the treatment and kept to strict dose intervals, then results looked pretty good (very small sample size - 4). The data presented is a little unclear, but shows promise.
The issue with tolerability lead them to develop a gel formulation for future burns trials, which has been used under the SAS with great results so far (the cases they've chosen to present anyway).
Yes, so long as the patient was able to tolerate the treatment...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.5¢ | 47.0¢ | $69.22K | 145.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14026 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 28197 | 7 |
View Market Depth
| Last trade - 12.41pm 07/08/2024 (20 minute delay) ? |
| RCE (ASX) Chart |